Stocks and Investing
Stocks and Investing
Tue, August 24, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, August 23, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, August 20, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jessica Fye Downgraded (APRE) to Sell on, Aug 20th, 2021
Jessica Fye of JP Morgan, Downgraded "Aprea Therapeutics, Inc." (APRE) to Sell on, Aug 20th, 2021.
Jessica has made no other calls on APRE in the last 4 months.
There are 4 other peers that have a rating on APRE. Out of the 4 peers that are also analyzing APRE, 3 agree with Jessica's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Fein of "HC Wainwright & Co." Maintained at Hold with Decreased Target to $80 on, Monday, August 16th, 2021
- Esther Hong of "Berenberg" Downgraded from Strong Buy to Hold on, Monday, August 16th, 2021
- Gregory Renza of "RBC Capital" Maintained at Hold with Decreased Target to $100 on, Friday, August 13th, 2021
This is the rating of the analyst that currently disagrees with Jessica
- Jeffrey Hung of "Morgan Stanley" Downgraded from Hold to Sell and Decreased Target to $60 on, Friday, August 13th, 2021
Contributing Sources